chrisvoncsefalvay/vaers-outcomes huggingface dataset:
immobile half body; right arm feels bloodless/feels blood less; right arm seems darker than the left; metallic feeling in mouth; numb hands; Soreness/Pain; This spontaneous case was reported by a consumer and describes the occurrence of MOBILITY DECREASED (immobile half body), FEELING ABNORMAL (right arm feels bloodless/feels blood less), SKIN DISCOLOURATION (right arm seems darker than the left), DYSGEUSIA (metallic feeling in mouth) and HYPOAESTHESIA (numb hands) in a 24-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025C21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Surgery (Stomach Surgery). Concomitant products included ETHINYLESTRADIOL, FERROUS FUMARATE, NORETHISTERONE ACETATE (LO LOESTRIN FE) for Birth control.    On 11-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-May-2021, the patient experienced MOBILITY DECREASED (immobile half body), FEELING ABNORMAL (right arm feels bloodless/feels blood less), SKIN DISCOLOURATION (right arm seems darker than the left), DYSGEUSIA (metallic feeling in mouth), HYPOAESTHESIA (numb hands) and VACCINATION SITE PAIN (Soreness/Pain). At the time of the report, MOBILITY DECREASED (immobile half body), FEELING ABNORMAL (right arm feels bloodless/feels blood less), SKIN DISCOLOURATION (right arm seems darker than the left), DYSGEUSIA (metallic feeling in mouth), HYPOAESTHESIA (numb hands) and VACCINATION SITE PAIN (Soreness/Pain) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment medications provided by the reporter.
diarrhea; This is a spontaneous report from contactable consumer (patient) from a Pfizer-sponsored program. A female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Lot Number- UNKNOWN) via an unspecified route of administration on 26Jan2021 as single dose for COVID-19 immunization. The patients medical history and concomitant medications were not reported. On 27Jan2021, patient experienced diarrhea all day. The outcome of event was unknown.  Information on the lot/batch number has been requested.  Follow-up (16Apr2021): This follow-up is being submitted to notify that the lot/batch number is not available despite the follow-up attempts made. Follow-up attempts have been completed and no further information is expected.
Developed an itching condition, have been under a doctors care since early March/Never had any kind of itching condition before/ itching with major areas on abdomen and back, but also affected scalp, arms, legs and buttocks; Injection site soreness; Rash; This spontaneous case was reported by a consumer and describes the occurrence of PRURITUS (Developed an itching condition, have been under a doctors care since early March/Never had any kind of itching condition before/ itching with major areas on abdomen and back, but also affected scalp, arms, legs and buttocks), VACCINATION SITE PAIN (Injection site soreness) and RASH (Rash) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 041M20A and 12M20A) for COVID-19 vaccination.     No Medical History information was reported.   On 28-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 24-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced PRURITUS (Developed an itching condition, have been under a doctors care since early March/Never had any kind of itching condition before/ itching with major areas on abdomen and back, but also affected scalp, arms, legs and buttocks), VACCINATION SITE PAIN (Injection site soreness) and RASH (Rash). At the time of the report, PRURITUS (Developed an itching condition, have been under a doctors care since early March/Never had any kind of itching condition before/ itching with major areas on abdomen and back, but also affected scalp, arms, legs and buttocks) and RASH (Rash) had not resolved and VACCINATION SITE PAIN (Injection site soreness) had resolved.            The patient has been undergoing treatment for this condition since March of 2021.  No relevant concomitant medications were reported.
This spontaneous report was received from a certified medical assistant and refers to a child of unknown age and gender. The patient's pertinent medical history, concurrent conditions and concomitant medications were not reported. ON 01-SEP-2015, the patient was vaccinated with an improperly stored dose of M-M-R II (lot # L007578 with an expiration date on 05-MAR-2017; dose and route of administration were not provided). No adverse effects were reported. No product quality complaint (PQC) was involved. This is one of several reports received from the same reporter. Additional information is not expected because there was no consent for further contact.
Minimum temperature in the fridge went down to 34.4 F/ temperature in the fridge went down to 33 or 34 last week; no adverse event; dose administered after excursion; This spontaneous case was reported by a nurse and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (dose administered after excursion), PRODUCT TEMPERATURE EXCURSION ISSUE (Minimum temperature in the fridge went down to 34.4 F/ temperature in the fridge went down to 33 or 34 last week) and NO ADVERSE EVENT (no adverse event) in a male patient of an unknown age who received mRNA-1273 (Spikevax) (batch no. 011B22A) for COVID-19 vaccination.     No Medical History information was reported.    On 06-Sep-2022, the patient received second dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On 06-Sep-2022, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (dose administered after excursion). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Minimum temperature in the fridge went down to 34.4 F/ temperature in the fridge went down to 33 or 34 last week) and NO ADVERSE EVENT (no adverse event). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (dose administered after excursion), PRODUCT TEMPERATURE EXCURSION ISSUE (Minimum temperature in the fridge went down to 34.4 F/ temperature in the fridge went down to 33 or 34 last week) and NO ADVERSE EVENT (no adverse event) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter considered NO ADVERSE EVENT (no adverse event) to be not related. No further causality assessments were provided for POOR QUALITY PRODUCT ADMINISTERED (dose administered after excursion) and PRODUCT TEMPERATURE EXCURSION ISSUE (Minimum temperature in the fridge went down to 34.4 F/ temperature in the fridge went down to 33 or 34 last week).    No concomitant medications was reported. The temperature in the fridge went down to 33 or 34 last week. It had been out of range for 100 days no one had checked it. The nurse is not sure if the Moderna vaccines were even in the fridge during that time.  The nurse had the DDLs. The probe was pushed in,and the state department had given them a new one It was reported that storage condition at the time of excursion in fridge was little bit below 36 degrees.  Minimum temperature reached to 34.4 F. The vial moved from freezer to refrigerator was 19-Aug-2022. 1 dose was administered and other doses was wasted. 1 vial punctured and no previous excursions. No treatment drug details was reported.
On the  day of injection I started with pain, but I on the second day a rash started on injection site, by the third day the rash area grew.
Intense muscle aches, severe fatigue, red, swollen, lump (approximately 1" diameter) at injection site all within 6 hours of vax. Most symptoms passed after approximately 32 hours, however, injection site reaction continues to grow (6" diameter) and is hard, itchy, swollen, and hot to the touch.
Rash occurred on legs same day 6-7 hours after injection. Next day rash spread entire body. Knees locked, feet turned out, arms hurt; no fever; rash now itchy. Rash - denies hives but small red bumps. Denies edema; dyspnea. Refer to PCP.
Ringworm like skin lesion around injection site for about one month. Pt has a history of uppper arm swelling after DTaP dose number 5 vaccine.
projectile vomiting x 1day; t102 2 hrs p/vax; screaming x 12hrs high pitched;
received the product menquadfi 2 times (with no reported adverse event); Initial information was received on 06-Dec-2022 regarding an unsolicited valid non-serious case received from a other health professional.  This case involves 11 years old male patient who received the product menquadfi 2 times (with no reported adverse event) after being vaccinated with MENINGOCOCCAL A-C-Y-W135 (T CONJ) VACCINE [MENQUADFI].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications included INFLUENZA VACCINE for Prophylactic vaccination.  On 01-Dec-2022, the patient received a 0.25 Total dose 1 of suspect MENINGOCOCCAL A-C-Y-W135 (T CONJ) VACCINE (strength: standard) (lot number: U7576AB, expiration date: 28-Feb-2025) via intramuscular route in the left arm. On 05-Dec-2022 he also received dose 2 dose of the same vaccine via intramuscular route in the right arm for Immunization (Imunisation).  On 05-DEC-2022 the patient developed a non-serious received the product menquadfi 2 times (with no reported adverse event) (extra dose administered) 4 days following the administration of MENINGOCOCCAL A-C-Y-W135 (T CONJ) VACCINE.  No lab data reported.  Action taken: not applicable.  It was not reported if the patient received a corrective treatment for the event.  Outcome: Unknown for the event received the product menquadfi 2 times (with no reported adverse event).  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
The Tuesday after the vaccine I have been unable to get my blood pressure under control.  I have been dizzy, light headed and my worst blood pressure reading was 151/109.  I debated to go to the emergency room because I was so weak but I waited it out.  I am going to a cardiologist on Monday  April 19th to try and get my blood pressure under control
Patient was vaccinated at 5:33 pm in the   room. During vaccination patient was screaming and struggling while mother was holding him down. Patient was very anxious and combative. Mother brought patient to wait in the car. Volunteer alerted staff that patient?s mother had concerns about patient?s symptoms at 5:40 pm. Staff came out to see patient in the car. Observed that patient vomited twice. Patient?s mother stated that he had sharp pain on right side of his head, was shaking and nodding off. She stated that his behavior was not normal. Post vomiting, patient stated that the pain in his head went away. 911 was called, patient?s mother refused ambulance due to potential long wait. Fire department arrived on scene. Patient?s vital signs were stable. Paramedics conveyed to mother that it seemed like it might be a post anxiety attack and to let their doctor know what occurred. Patient?s mother decided to take patient home and will observe if any changes occur.
She got the vaccine, was feeling fine, went to church and did her normal things for the rest of the day,  and approximately 24 hours after the vaccine around 12:30 to 1:00 and started getting chills.  She wrapped up in a blanket and took a nap.  Then approximately 1:30 PM she had blurry vision, couldn't see clear, and she felt very, very faint like she was going to faint and was sitting in a chair and continued to sit there for a few minutes.  Then she was weak after that, and then a while later she was okay.
Patient received Covid vaccine on L deltoid. Pt waited in clinic for 15 mins and that's when reaction was noticed.  Provider came to room to evaluate. Provider observed multiple large, erythematous wheels on skin of lower half of face and neck. Also one small erythematous, irregular shaped wheel on left upper arm, at site of injection. No lip/mouth/through swelling. No wheezing. No other symptoms. Patient was given 10mls benadryl and observed for an additional 15 minutes. Following observation period itching resolved, wheels reduced in size and redness improved. Cardiac and pulmonary exam continued to be normal. Patient was sent home with recommendations to observe patient closely and give 10mls of benadryl 12.5mg/5mls liquid every 6-8 hours as needed for hives/itching.
This spontaneous report was received from a 70 year old female patient regarding herself with no drug reactions or allergies. The patient has no pertinent medical history. On 27-NOV-2012, the patient was vaccinated with a dose 1 injection live ZOSTAVAX(lot number, expiry date, route and dose were not reported). Concomitant medications included COUMADIN, unspecified drug CARTIZAM ,unspecified thyroid medication, metoprolol and ZOLEFT. The patient had shingles break out twice on her right arm after receiving ZOSTAVAX. Approximately on 04-DEC-2012 (reported as a week after injection), the patient experienced the first case of shingles. No treatment was given. It lasted about four weeks and then began to go away. Approximately on 01-JAN-2013, the first case of shingles had resolved. Approximately on an unknown date in January 2013, the patient had another break out of shingles. Since an unknown date, the patient had trouble sleeping. The patient sought medical attention (saw her physician) and no treatment was given. No laboratory test was performed. At the time of this report, the patient had not recovered from shingles. Outcome of the event trouble sleeping was unknown. Additional information has been requested.
30 min after vaccine, noted to appear pale, nauseated, abd pain and faint pink rash on body., lasted about 20 min.
02/15/2004 Received flu and PPV 23 AM 101.4 temp 8:30 or 9:00PM. Ice packs applied Wed night. All day Thurs. Took Ibuprofen yesterday and this AM (I called private MD nurse at office to call pt at home today). Referred to MD if not improved.
Patient came in for FLU shot at Pharmacy complaining of "sore on arm from shot at other pharmacy".  After reviewing Shots Registry, he received shot on 5/6/19. Appears to be a nickel-sized sore on arm. Referred to dermatologist or PCP.
Information has been received on 14-MAY-2018 regarding a case in litigation from a lawyer and a male consumer of unknown age. The patient's concurrent conditions, medical history and concomitant medications are unknown. On or about 21-JAN-2014, the patient was inoculated with ZOSTAVAX (lot number and expiration unknown) unknown route at a pharmacy as recommended for routine adult health maintenance and for the prevention of shingles. The vaccine did not prevent shingles as intended, and the patient subsequently contracted a persistent strain of herpes zoster. On or about 05-JUN-2017, the patient was treated at a dermatology clinic for a blistering vesicular outbreak, which was diagnosed as shingles. The patient has been prescribed valacyclovir and acetaminophen-hydrocodone to manage his painful symptoms and chronic pain. As a direct and proximate result of the ZOSTAVAX and/or despite receiving the ZOSTAVAX for long-term prevention of shingles, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses and pain and suffering and other damages. Additional information has been requested.
Systemic: Dizziness / Lightheadness-Mild, Systemic: Flushed / Sweating-Mild, Additional Details: 5 mins after receiving vaccine, patient complained of lightheadedness and became diaphoretic. Was assisted to supine position on the examining table with legs elevated. Vital signs continuously monitored and pulse was in the 40's and 50's. EMS activated after 20 mins of no resolution in symptoms. Patient discharged home after evaluation by EMS personnel. Called patient today 05/15/2023 and he sated he is felling better and is back at school
1 week after 2nd Lyme shot, wrist, fingers, & ankle joints began to ache and still ache almost 18 mo later. * 1st shot was 4/25/00
Sever bruising at injection site about half a dollar bill size; Aches in joints; Nausea; Headache; Tiredness; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration in the right arm on 11Apr2021 at 15:45 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. Medical history included chronic health condition. The patient had known allergies to bee stings. Concomitant medications were not reported. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL1283) via an unspecified route of administration in the right arm on 13Mar2021 at 15:30 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 12Apr2021, the patient experienced severe bruising at injection site about half a dollar bill size, nausea, aches in joints, headache and tiredness. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the reported events. The clinical outcomes of severe bruising at injection site about half a dollar bill size, nausea, aches in joints, headache and tiredness were not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Extreme joint pain; Sore arm; Fatigue; This is a spontaneous report from a non-contactable consumer or other non hcp.   A female patient of unspecified age 25 (unknown units)  received bnt162b2 (BNT162B2), (Formulation: Solution for injection, Batch/Lot Number: Unknown; Expiration Date: Unknown) dose 2, single via an unspecified route of administration on 26Apr2021 for covid-19 immunisation. The patient medical history was not reported. The patient's concomitant medications were not reported. Historical vaccine received bnt162b2 (BNT162B2), (Formulation: Solution for injection, Batch/Lot Number: Unknown; Expiration Date: Unknown) dose 1, single via an unspecified route of administration on an unknown date for covid-19 immunisation. On 27Apr2021 (Starting 24 hours after injection) the patient experienced extreme joint pain and fatigue and sore arm. The outcome of all events was not recovered.   No follow-up attempts are possible; information about lot/batch number cannot be obtained
I administered the flu vaccine her arm got a swollen, hard knot at the site of injection.
Lightheaded with mild nausea.  Cardiac monitor showed occasional PAC followed by a sinus pause and junctional escape beat.  resolved with PO fluids and rest.
Today I felt extremely fatigued. Could not move my left arm very much. Pretty bad chills and a fever of 101
numbness and tingling; low back pain; prickling sensation; cervogenic headaches; muscle pain; nerve pain; This spontaneous case was reported by a consumer and describes the occurrence of PARAESTHESIA (numbness and tingling), NEURALGIA (nerve pain), BACK PAIN (low back pain), PAIN (prickling sensation) and MYALGIA (muscle pain) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Cervical discectomy (Disc replacement in cervical small annular tear in C4).   On 10-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 10-Feb-2021, the patient experienced NEURALGIA (nerve pain) and MYALGIA (muscle pain). On an unknown date, the patient experienced PARAESTHESIA (numbness and tingling), BACK PAIN (low back pain), PAIN (prickling sensation) and HEADACHE (cervogenic headaches). The patient was treated with GABAPENTIN at an unspecified dose and frequency. At the time of the report, PARAESTHESIA (numbness and tingling), NEURALGIA (nerve pain), BACK PAIN (low back pain), PAIN (prickling sensation), MYALGIA (muscle pain) and HEADACHE (cervogenic headaches) outcome was unknown.            No concomitant medications were reported.  Action taken with mRNA-1273 in response to the event was not applicable.
Shortness of breath, leg weakness (within 2 months of shot) feet and hand tingling. Blood work went crazy. Loss of hand strength. Was unable to walk. Hurt all the time. Lost 25 pounds in one month (or less time). They put me thru all sorts of tests finally sent me to a neurologist - spinal tap confirmed Guillain-Barre - 6 day treatments 7-wks total treatments were given. CIDP now.
Pt developed "strange feeling" then was noted to have dysarthria and lip swelling/facial droop. Sxs began about 6 hours after the vaccine. She was seen in the ER at Medical Center where she underwent a neurological evaluation and was diagnosed with Bell's Palsy and was treated with prednisone and VALTREX.
patient presented to emergency department on 12/19/21 with shortness of breath patient was diagnosed with covid-19 on 12/15/21 and sent to a nursing home patient was admitted to the hospital for further management of acute respiratory failure with hypoxia patient was discharge to nursing home on 1/7/22